Aclaris Therapeutics (ACRS) Intangibles (2017 - 2023)
Aclaris Therapeutics (ACRS) posted quarterly Intangibles of $751000.0 for Q4 2023, down 89.82% year-over-year from $7.4 million in Q4 2022, and down 89.82% quarter-over-quarter from $7.4 million in Q3 2023.
Aclaris Therapeutics (ACRS) Intangibles (2017 - 2023) Analysis & Trends
Aclaris Therapeutics' Intangibles history runs 7 years deep, the most recent figure standing at $751000.0 for Q4 2023.
- In Q4 2023, Intangibles fell 89.82% year-over-year to $751000.0; the TTM figure through Dec 2023 stood at $751000.0 (down 89.82% YoY), while the FY2023 annual figure was $751000.0, down 89.82% from the prior year.
- Intangibles for Q4 2023 stood at $751000.0, down from $7.4 million in the prior quarter.
- The five-year high for Intangibles was $73.8 million in Q1 2019, with the low at $751000.0 in Q4 2023.
- The 5-year median for Intangibles is $7.1 million (2020), against an average of $13.3 million.
- The sharpest annual moves came in 2019 and 2020: Intangibles jumped 906.75% in 2019, then tumbled 90.0% in 2020.
- Aclaris Therapeutics' Intangibles stood at $7.2 million in 2019, then retreated by 1.06% to $7.1 million in 2020, then decreased by 1.05% to $7.0 million in 2021, then advanced by 4.71% to $7.4 million in 2022, then tumbled by 89.82% to $751000.0 in 2023.
- Business Quant data shows ACRS's Intangibles at $751000.0 in Q4 2023, $7.4 million in Q3 2023, and $6.9 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 751,000.00 |
| Sep 30, 2023 | 7.38 Mn |
| Jun 30, 2023 | 6.94 Mn |
| Mar 31, 2023 | 6.95 Mn |
| Dec 31, 2022 | 7.38 Mn |
| Sep 30, 2022 | 6.99 Mn |
| Jun 30, 2022 | 7.01 Mn |
| Mar 31, 2022 | 7.03 Mn |
| Dec 31, 2021 | 7.05 Mn |
| Sep 30, 2021 | 7.07 Mn |
| Jun 30, 2021 | 7.38 Mn |
| Mar 31, 2021 | 7.11 Mn |
| Dec 31, 2020 | 7.12 Mn |
| Sep 30, 2020 | 7.38 Mn |
| Jun 30, 2020 | 7.16 Mn |
| Mar 31, 2020 | 7.38 Mn |
| Dec 31, 2019 | 7.20 Mn |
| Sep 30, 2019 | 7.22 Mn |
| Jun 30, 2019 | 69.78 Mn |
| Mar 31, 2019 | 73.80 Mn |